Vassiliki L Tsikitis1, Ian White2, Motomi Mori3, Amiee Potter4, Achyut Bhattcharyya5, Stanley R Hamilton6, Julie Buckmeier5, Peter Lance5, Patricia Thompson5. 1. Division of Colorectal Surgery, Department of Surgery, Oregon Health and Science University, 3181 S.W. Sam Jackson Park Road, L223A, Portland, OR 97239, USA. Electronic address: tsikitis@ohsu.edu. 2. Division of Colorectal Surgery, Department of Surgery, Oregon Health and Science University, 3181 S.W. Sam Jackson Park Road, L223A, Portland, OR 97239, USA. 3. Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA; Integrated Genomics Laboratory, Oregon Health and Science University, Portland, OR, USA. 4. Integrated Genomics Laboratory, Oregon Health and Science University, Portland, OR, USA. 5. Arizona Cancer Center, Tucson, AZ, USA. 6. Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Abstract
BACKGROUND: MicroRNA (miR)-320a, miR-145, and miR-192 have been shown to play a role in colorectal carcinogenesis and metastasis. We examined if there is a difference in expression during the histologic progression from normal mucosa (NM) to high-grade dysplastic adenomas (HG). METHODS: Genome-wide miRNA expression profiling was performed on 113 colon adenomas. Information included histologic type, tumor grade, location, sex, age, family, and smoking history. A 2-way ANOVA was performed to evaluate the effect of the following factors adjusted for scan dates: location, sex, age, family history, smoking, and histology. RESULTS: The expression of miR-320a increased; miR-145 and miR-192 expression decreased (P < .0001), with higher histologic grade, and were independent of age, sex, family history, and smoking status. CONCLUSIONS: The miRs studied had statistically significant changes in expression with progression of histologic grade. These changes may signify progression of normal mucosa to HG and potentially serve as early markers for disease progression and differentiating high- from low-risk adenomas.
BACKGROUND:MicroRNA (miR)-320a, miR-145, and miR-192 have been shown to play a role in colorectal carcinogenesis and metastasis. We examined if there is a difference in expression during the histologic progression from normal mucosa (NM) to high-grade dysplastic adenomas (HG). METHODS: Genome-wide miRNA expression profiling was performed on 113 colon adenomas. Information included histologic type, tumor grade, location, sex, age, family, and smoking history. A 2-way ANOVA was performed to evaluate the effect of the following factors adjusted for scan dates: location, sex, age, family history, smoking, and histology. RESULTS: The expression of miR-320a increased; miR-145 and miR-192 expression decreased (P < .0001), with higher histologic grade, and were independent of age, sex, family history, and smoking status. CONCLUSIONS: The miRs studied had statistically significant changes in expression with progression of histologic grade. These changes may signify progression of normal mucosa to HG and potentially serve as early markers for disease progression and differentiating high- from low-risk adenomas.
Authors: David A Lieberman; Douglas K Rex; Sidney J Winawer; Francis M Giardiello; David A Johnson; Theodore R Levin Journal: Gastroenterology Date: 2012-07-03 Impact factor: 22.682
Authors: David S Alberts; María Elena Martínez; Lisa M Hess; Janine G Einspahr; Sylvan B Green; A K Bhattacharyya; Jose Guillen; Mary Krutzsch; Ashok K Batta; Gerald Salen; Liane Fales; Kris Koonce; Dianne Parish; Mary Clouser; Denise Roe; Peter Lance Journal: J Natl Cancer Inst Date: 2005-06-01 Impact factor: 13.506
Authors: Francesc Balaguer; Leticia Moreira; Juan Jose Lozano; Alexander Link; Georgina Ramirez; Yan Shen; Miriam Cuatrecasas; Mildred Arnold; Stephen J Meltzer; Sapna Syngal; Elena Stoffel; Rodrigo Jover; Xavier Llor; Antoni Castells; C Richard Boland; Meritxell Gironella; Ajay Goel Journal: Clin Cancer Res Date: 2011-08-15 Impact factor: 12.531
Authors: Clemens L Bockmeyer; Matthias Christgen; Mirco Müller; Sebastian Fischer; Philipp Ahrens; Florian Länger; Hans Kreipe; Ulrich Lehmann Journal: Breast Cancer Res Treat Date: 2011-03-17 Impact factor: 4.872
Authors: Troels Schepeler; Jørgen T Reinert; Marie S Ostenfeld; Lise L Christensen; Asli N Silahtaroglu; Lars Dyrskjøt; Carsten Wiuf; Frank J Sørensen; Mogens Kruhøffer; Søren Laurberg; Sakari Kauppinen; Torben F Ørntoft; Claus L Andersen Journal: Cancer Res Date: 2008-08-01 Impact factor: 12.701
Authors: O Slaby; M Svoboda; P Fabian; T Smerdova; D Knoflickova; M Bednarikova; R Nenutil; R Vyzula Journal: Oncology Date: 2008-01-15 Impact factor: 2.935
Authors: Anna Siskova; Klara Cervena; Jan Kral; Tomas Hucl; Pavel Vodicka; Veronika Vymetalkova Journal: Int J Mol Sci Date: 2020-05-05 Impact factor: 5.923